The opioid crisis continues to claim over 70,000 American lives annually, yet evidence-based medication interventions remain underutilized despite proven efficacy. A comprehensive clinical review reveals how three distinct pharmaceutical approaches—maintenance therapy, withdrawal management, and overdose reversal—form an integrated treatment framework that could dramatically improve outcomes for millions struggling with opioid dependence. The analysis examines methadone, buprenorphine, and naltrexone for long-term maintenance; alpha-2 agonists and symptomatic medications for withdrawal management; and naloxone formulations for emergency overdose intervention. Each category addresses different phases of the addiction cycle, from acute crisis to sustained recovery. Methadone and buprenorphine, both opioid receptor agonists, reduce cravings and withdrawal symptoms while blocking euphoric effects of illicit opioids. Naltrexone, an antagonist, prevents opioid effects entirely but requires complete detoxification first. For withdrawal, non-opioid medications like clonidine manage autonomic symptoms while comfort medications address nausea, insomnia, and anxiety. This medication-assisted treatment approach represents a paradigm shift from abstinence-only models that historically showed poor success rates. The review emphasizes that these interventions work best within comprehensive care programs including counseling and social support. However, significant barriers persist: limited prescriber training, insurance coverage gaps, and persistent stigma around medication-assisted treatment. The evidence strongly supports expanding access to these proven interventions, particularly in underserved communities where opioid mortality rates continue climbing despite available solutions.